Get the Stockscreener App
29.46
2.58%
0.74
Agios Pharmaceuticals Inc stock is traded at $29.46, with a volume of 1.14M.
It is up +2.58% in the last 24 hours and up +3.66% over the past month.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.
See More
Previous Close:
$28.72
Open:
$28.8
24h Volume:
1.14M
Relative Volume:
1.08
Market Cap:
$1.75B
Revenue:
$66.05M
Net Income/Loss:
$-422.60M
P/E Ratio:
-4.0629
EPS:
-7.251
Net Cash Flow:
$-384.73M
1W Performance:
+4.14%
1M Performance:
+3.66%
6M Performance:
+8.03%
1Y Performance:
-14.61%
1-Day Range:
$28.51
$30.23
1-Week Range:
$26.89
$30.23
52-Week Range:
$22.24
$46.00
Agios Pharmaceuticals Inc Stock (AGIO) Company Profile
Name
Agios Pharmaceuticals Inc
Sector
Industry
Phone
617-649-8600
Address
88 SIDNEY STREET, CAMBRIDGE, MA
Compare AGIO vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AGIO
Agios Pharmaceuticals Inc
|
29.46 | 1.75B | 66.05M | -422.60M | -384.73M | -7.251 |
VRTX
Vertex Pharmaceuticals Inc
|
444.93 | 112.92B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
612.14 | 64.18B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
893.52 | 55.57B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.85 | 37.76B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
153.87 | 32.71B | 742.00K | -1.37B | -1.07B | -7.0731 |
Agios Pharmaceuticals Inc Stock (AGIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-20-26 | Reiterated | H.C. Wainwright | Buy |
| Nov-24-25 | Initiated | Truist | Buy |
| Nov-20-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Nov-19-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Feb-24-25 | Initiated | H.C. Wainwright | Buy |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Oct-10-24 | Resumed | Raymond James | Outperform |
| Sep-27-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Feb-08-24 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-03-23 | Initiated | Piper Sandler | Overweight |
| Nov-17-22 | Upgrade | Goldman | Sell → Neutral |
| Jul-27-22 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Dec-03-21 | Initiated | BofA Securities | Buy |
| Jul-30-21 | Downgrade | Goldman | Neutral → Sell |
| Jul-01-21 | Initiated | Raymond James | Mkt Perform |
| Jun-10-21 | Initiated | H.C. Wainwright | Buy |
| Mar-01-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Mar-01-21 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Feb-26-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Oct-22-20 | Upgrade | Barclays | Equal Weight → Overweight |
| Mar-04-20 | Initiated | Barclays | Equal Weight |
| Nov-26-19 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-23-19 | Upgrade | Guggenheim | Neutral → Buy |
| May-23-19 | Resumed | Goldman | Neutral |
| Feb-15-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Sep-25-18 | Initiated | Leerink Partners | Mkt Perform |
| May-23-18 | Initiated | Citigroup | Buy |
| Apr-11-18 | Reiterated | Credit Suisse | Outperform |
| Feb-15-18 | Reiterated | Needham | Buy |
| Feb-15-18 | Reiterated | SunTrust | Buy |
| Sep-15-17 | Initiated | RBC Capital Mkts | Outperform |
| Aug-10-17 | Reiterated | Needham | Buy |
| Aug-08-17 | Reiterated | SunTrust | Buy |
| Aug-02-17 | Upgrade | Leerink Partners | Mkt Perform → Outperform |
| Jun-26-17 | Downgrade | Janney | Buy → Neutral |
| Jan-17-17 | Upgrade | Oppenheimer | Perform → Outperform |
| Oct-24-16 | Initiated | Needham | Buy |
| Jun-13-16 | Upgrade | JP Morgan | Neutral → Overweight |
| May-18-16 | Reiterated | SunTrust | Buy |
View All
Agios Pharmaceuticals Inc Stock (AGIO) Latest News
Agios Pharmaceuticals touts mitapivat gains despite sickle cell pain miss - MSN
Agios Pharmaceuticals Touts Mitapivat Gains Despite Sickle Cell Pain Miss - Yahoo Finance
AGIO: Mitapivat shows durable efficacy in rare hematology, supporting growth and pipeline expansion - TradingView
Technical Reactions to AGIO Trends in Macro Strategies - Stock Traders Daily
Agios presents detailed mitapivat trial results for sickle cell By Investing.com - Investing.com Australia
Agios presents detailed mitapivat trial results for sickle cell - Investing.com
Agios Pharmaceuticals Reports Positive Phase 3 Results for Mitapivat in Sickle Cell Disease, Highlighting Hemoglobin Response and Reduced Transfusion Burden - Quiver Quantitative
Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong ... - Caledonian Record
Sickle cell patients needed fewer transfusions with Agios pill in Phase 3 - Stock Titan
Agios to discontinue candidate for myelodysplastic syndromes - MSN
Agios Pharmaceuticals (NASDAQ:AGIO) Given New $31.00 Price Target at JPMorgan Chase & Co. - MarketBeat
GW&K Investment Management LLC Purchases 354,359 Shares of Agios Pharmaceuticals, Inc. $AGIO - MarketBeat
Capital International Investors Buys New Position in Agios Pharmaceuticals, Inc. $AGIO - MarketBeat
Agios Pharmaceuticals, Inc. $AGIO Shares Bought by BNP Paribas Financial Markets - MarketBeat
‘Disciplined’ $665M deal moves Oscotec’s cevidoplenib to Agios - BioWorld News
Eyes on Asia: Olix, Agios, Eli Lilly - BioXconomy
Analysts’ Top Healthcare Picks: McKesson (MCK), Agios Pharma (AGIO) - The Globe and Mail
BofA Securities Maintains Agios Pharmaceuticals(AGIO.US) With Buy Rating, Maintains Target Price $40 - Moomoo
Alpha Thalassemia Market Emerging as a High-Growth Healthcare Investment Space Through 2036 – DelveInsight | Forma Therapeutics, Genmedicn Biopharma, Bristol-Myers Squibb, Agios Pharma - Barchart.com
Erste Asset Management GmbH Acquires 40,000 Shares of Agios Pharmaceuticals, Inc. $AGIO - MarketBeat
The week in pharma: action, reaction and insight – week to June 5, 2026 - The Pharma Letter
Why Agios Pharmaceuticals (AGIO) Is Down 5.4% After Overhauling Its Hematology PortfolioAnd What's Next - Sahm
Agios Pharmaceuticals | 144: Notice of proposed sale of securities pursuant to Rule 144 - Moomoo
Q2 EPS Estimate for Agios Pharmaceuticals Reduced by Analyst - MarketBeat
AGIO secures global rights to late-stage rare blood disorder candidate - MSN
How The Tebapivat Setback Is Reframing The Story For Agios Pharmaceuticals (AGIO) - Yahoo Finance
AGIO Secures Global Rights to Late-Stage Rare Blood Disorder Candidate - The Globe and Mail
Trading the Move, Not the Narrative: (AGIO) Edition - Stock Traders Daily
Analysts Are Bullish on Top Healthcare Stocks: Agios Pharma (AGIO), Cogent Biosciences (COGT) - The Globe and Mail
Agios inks global licensing agreement with Oscotec - The Pharma Letter
Oscotec Signs Up to $665 Million Licensing Deal with Agios Pharmaceuticals for Autoimmune Drug Candidate Cevidoplenib - 알파경제
Agios Halts Tebapivat Trials As Sickle Cell Focus Shapes Valuation - Sahm
Agios Pharmaceuticals, Inc. (AGIO) Discusses Global License Agreement for Cevidoplenib and Strategic Expansion in Rare HematologySlideshow (NASDAQ:AGIO) 2026-06-01 - Seeking Alpha
Agios Pharmaceuticals licenses global rights to Oscotec's SYK inhibitor cevidoplenib - Yahoo Finance
Agios scraps blood cancer drug program after study miss - AOL.com
AGIO Halts Tebapivat Development in Myelodysplastic Syndromes - The Globe and Mail
AGIO: Cevidoplenib licensed for ITP, with strong phase II data and phase III planned for 2028 - TradingView
Agios licenses oral SYK inhibitor for rare blood disorder By Investing.com - Investing.com South Africa
Agios Pharmaceuticals (AGIO) Forms Licensing Deal for Cevidoplen - GuruFocus
AGIO: Exclusive global license for cevidoplenib expands rare hematology pipeline and targets ITP - TradingView
Agios licenses oral SYK inhibitor for rare blood disorder - Investing.com UK
Agios Enters Exclusive Global License Agreement with Oscotec to Develop and Commercialize Next-Generation SYK Inhibitor Cevidoplenib - The Manila Times
Agios Pharmaceuticals Secures Exclusive Global Rights to Next-Generation SYK Inhibitor Cevidoplenib for Immune Thrombocytopenia Treatment - Quiver Quantitative
Agios Enters Exclusive Global License Agreement with Oscotec to Develop and Commercialize ... - Caledonian Record
Rare blood disorder drug deal gives Agios shot at $1B U.S. sales - Stock Titan
Oscotec licenses autoimmune drug to US Agios in deal up to 1 trillion wonCHOSUNBIZ - Chosunbiz
Agios slides after discontinuing development of tebapivat in myelodysplastic syndromes (AGIO) - MSN
Agios halts tebapivat development for blood disorder - Investing.com UK
AGIO Maintained by B of A Securities -- Price Target Lowered to $40 - GuruFocus
Agios: 'Sell' On Tebapivat Setback LR-MDS And Competitive PK Activator Drug Class - Seeking Alpha
Agios Pharmaceuticals, Inc. Stock 12‑Month Price Target Cut to $40.88, Implies 34% Upside - TradingView
Agios Pharmaceuticals Inc Stock (AGIO) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.04%
0.76%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):